危重症患者单核细胞和中性粒细胞功能的免疫监测：从脓毒症和/或创伤到新型冠状病毒肺炎
Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19.
作者信息
Udovicic Ivo, Stanojevic Ivan, Djordjevic Dragan, Zeba Snjezana, Rondovic Goran, Abazovic Tanja, Lazic Srdjan, Vojvodic Danilo, To Kendrick, Abazovic Dzihan, Khan Wasim, Surbatovic Maja
机构信息
Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia.
Faculty of Medicine of the Military Medical Academy, University of Defence, Crnotravska 17, 11000 Belgrade, Serbia.
出版信息
J Clin Med. 2021 Dec 12;10(24):5815. doi: 10.3390/jcm10245815.
Abstract
Immune cells and mediators play a crucial role in the critical care setting but are understudied. This review explores the concept of sepsis and/or injury-induced immunosuppression and immuno-inflammatory response in COVID-19 and reiterates the need for more accurate functional immunomonitoring of monocyte and neutrophil function in these critically ill patients. in addition, the feasibility of circulating and cell-surface immune biomarkers as predictors of infection and/or outcome in critically ill patients is explored. It is clear that, for critically ill, one size does not fit all and that immune phenotyping of critically ill patients may allow the development of a more personalized approach with tailored immunotherapy for the specific patient. In addition, at this point in time, caution is advised regarding the quality of evidence of some COVID-19 studies in the literature.
摘要
免疫细胞和介质在重症监护环境中起着关键作用，但尚未得到充分研究。本综述探讨了脓毒症和/或损伤诱导的免疫抑制以及新型冠状病毒肺炎（COVID-19）中的免疫炎症反应概念，并重申了对这些重症患者的单核细胞和中性粒细胞功能进行更准确的功能免疫监测的必要性。此外，还探讨了循环和细胞表面免疫生物标志物作为重症患者感染和/或预后预测指标的可行性。显然，对于重症患者来说，一种方法并不适用于所有人，对重症患者进行免疫表型分析可能有助于开发更个性化的方法，为特定患者量身定制免疫疗法。此外，在目前这个时间点，对于文献中一些COVID-19研究的证据质量需谨慎对待。
相似文献
1
Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19.危重症患者单核细胞和中性粒细胞功能的免疫监测：从脓毒症和/或创伤到新型冠状病毒肺炎
J Clin Med. 2021 Dec 12;10(24):5815. doi: 10.3390/jcm10245815.
2
Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome.急性呼吸窘迫综合征的危重症 COVID-19 患者中 IFN-I 活性和免疫特征的纵向评估。
Crit Care. 2021 Apr 12;25(1):140. doi: 10.1186/s13054-021-03558-w.
3
4
[The prognostic value of serum procalcitonin on severity of illness in non-sepsis critically ill patients].[血清降钙素原对非脓毒症危重症患者病情严重程度的预后价值]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016 Aug;28(8):688-93. doi: 10.3760/cma.j.issn.2095-4352.2016.08.004.
5
The role of neutrophil chemotaxis activity as an immunologic biomarker to predict mortality in critically-ill patients with severe sepsis.中性粒细胞趋化活性作为免疫生物标志物预测严重脓毒症危重症患者死亡率的作用。
J Crit Care. 2020 Apr;56:215-221. doi: 10.1016/j.jcrc.2020.01.020. Epub 2020 Jan 17.
6
The REAnimation Low Immune Status Markers (REALISM) project: a protocol for broad characterisation and follow-up of injury-induced immunosuppression in intensive care unit (ICU) critically ill patients.复苏低免疫状态标志物（REALISM）项目：一项针对重症监护病房（ICU）危重症患者损伤诱导免疫抑制进行广泛特征描述和随访的方案。
BMJ Open. 2017 Jun 21;7(6):e015734. doi: 10.1136/bmjopen-2016-015734.
7
Immunoinflammatory response in critically ill patients: severe sepsis and/or trauma.危重症患者的免疫炎症反应：严重脓毒症和/或创伤。
Mediators Inflamm. 2013;2013:362793. doi: 10.1155/2013/362793. Epub 2013 Nov 24.
8
Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.前沿科学：脓毒症患者的免疫功能缺陷与PD-1或PD-L1表达相关，且可通过靶向PD-1或PD-L1的抗体得以恢复。
J Leukoc Biol. 2016 Dec;100(6):1239-1254. doi: 10.1189/jlb.4HI0616-255R. Epub 2016 Sep 26.
9
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.围生期组织来源的间充质干细胞治疗危重症 COVID-19 诱导的 ARDS 患者：病例系列。
Stem Cell Res Ther. 2021 Jan 29;12(1):91. doi: 10.1186/s13287-021-02165-4.
10
Red blood cell transfusion results in adhesion of neutrophils in human endotoxemia and in critically ill patients with sepsis.红细胞输注导致人类内毒素血症和脓毒症危重症患者中性粒细胞黏附。
Transfusion. 2020 Feb;60(2):294-302. doi: 10.1111/trf.15613. Epub 2019 Dec 5.
引用本文的文献
1
Enhancing sepsis management: the role of dynamic heparin-binding protein monitoring in elderly patients.加强脓毒症管理：动态肝素结合蛋白监测在老年患者中的作用
Front Med (Lausanne). 2025 Jun 11;12:1538515. doi: 10.3389/fmed.2025.1538515. eCollection 2025.
2
Predictive value of hematologic indices on weaning from mechanical ventilation and 30-day mortality in patients with traumatic brain injury in an intensive care unit: A retrospective analysis of MIMIC-IV data.重症监护病房中创伤性脑损伤患者血液学指标对机械通气撤机及30天死亡率的预测价值：基于MIMIC-IV数据的回顾性分析
Neurotherapeutics. 2025 Apr;22(3):e00559. doi: 10.1016/j.neurot.2025.e00559. Epub 2025 Feb 25.
3
Navigating Hemorrhagic Shock: Biomarkers, Therapies, and Challenges in Clinical Care.应对失血性休克：生物标志物、治疗方法及临床护理中的挑战
Biomedicines. 2024 Dec 17;12(12):2864. doi: 10.3390/biomedicines12122864.
4
A Future Blood Test to Detect Cerebral Aneurysms.一种未来用于检测脑动脉瘤的血液检测方法。
Cell Mol Neurobiol. 2023 Aug;43(6):2697-2711. doi: 10.1007/s10571-023-01346-4. Epub 2023 Apr 12.
5
Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis.脓毒症免疫麻痹中单核细胞 HLA-DR 的作用及治疗性 GM-CSF 的作用机制。
Front Immunol. 2023 Feb 7;14:1130214. doi: 10.3389/fimmu.2023.1130214. eCollection 2023.
6
Single-cell transcriptome profiling reveals heterogeneous neutrophils with prognostic values in sepsis.单细胞转录组分析揭示脓毒症中具有预后价值的异质性中性粒细胞。
iScience. 2022 Oct 7;25(11):105301. doi: 10.1016/j.isci.2022.105301. eCollection 2022 Nov 18.
7
From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?从细胞因子风暴到细胞因子微风：免疫发病机制的经验教训是否改善了中重度新冠肺炎的免疫调节治疗？
Biomedicines. 2022 Oct 18;10(10):2620. doi: 10.3390/biomedicines10102620.
本文引用的文献
1
Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry.接受白细胞介素 6 受体拮抗剂和皮质类固醇治疗的危重症机械通气 COVID-19 患者的临床特征和结局：一项来自多国登记处的初步报告。
Eur J Med Res. 2021 Oct 2;26(1):117. doi: 10.1186/s40001-021-00591-x.
2
Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury.免疫谱分析显示，在各种严重损伤病因的患者中，迟发性获得性免疫缺陷具有共同的免疫特征。
Crit Care Med. 2022 Apr 1;50(4):565-575. doi: 10.1097/CCM.0000000000005270.
3
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.早期使用依那西普联合可溶性尿激酶型纤溶酶原激活物受体血浆水平指导 COVID-19 治疗：一项双盲、随机对照 3 期试验。
Nat Med. 2021 Oct;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z. Epub 2021 Sep 3.
4
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis.阿那白滞素对新型冠状病毒肺炎患者死亡率的影响：一项系统评价和患者水平的荟萃分析。
Lancet Rheumatol. 2021 Oct;3(10):e690-e697. doi: 10.1016/S2665-9913(21)00216-2. Epub 2021 Aug 9.
5
High expression of neutrophil and monocyte CD64 with simultaneous lack of upregulation of adhesion receptors CD11b, CD162, CD15, CD65 on neutrophils in severe COVID-19.在重症新型冠状病毒肺炎中，中性粒细胞和单核细胞CD64高表达，同时中性粒细胞上的黏附受体CD11b、CD162、CD15、CD65缺乏上调。
Ther Adv Infect Dis. 2021 Jul 31;8:20499361211034065. doi: 10.1177/20499361211034065. eCollection 2021 Jan-Dec.
6
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.新冠肺炎危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
7
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
8
Surviving Covid-19 with Heparin?使用肝素治疗新冠病毒肺炎能否存活？
N Engl J Med. 2021 Aug 26;385(9):845-846. doi: 10.1056/NEJMe2111151. Epub 2021 Aug 4.
9
Quantifying the Burden of Viral Sepsis During the Coronavirus Disease 2019 Pandemic and Beyond.量化2019年冠状病毒病大流行期间及之后病毒性脓毒症的负担
Crit Care Med. 2021 Dec 1;49(12):2140-2143. doi: 10.1097/CCM.0000000000005207.
10
IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How?用于新冠病毒病住院患者的白细胞介素-6受体拮抗剂疗法：适用人群、时机及方式？
JAMA. 2021 Aug 10;326(6):483-485. doi: 10.1001/jama.2021.11121.
Zotero 插件